lnth-20240222
FALSE000152103600015210362024-02-222024-02-22

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2024
LANTHEUS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3656935-2318913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
201 Burlington Road, South Building, Bedford, MA
01730
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978671-8001
Not Applicable
(Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareLNTHThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02.     Results of Operations and Financial Condition.
On February 22, 2024, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and twelve months ended December 31, 2023. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*    Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
LANTHEUS HOLDINGS, INC.
By:
/s/ Eric Green
Name:
Eric Green
Title:
Vice President and Deputy General Counsel
Date: February 22, 2024
 


Document

Exhibit 99.1
https://cdn.kscope.io/bc060286194c76855edd92fd2996a024-newlantheuslogoa.jpg
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023
GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023
GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023
Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023
Net cash provided by operating activities was $112.3 million and $305.3 million for the fourth quarter and full year 2023 and free cash flow of $100.2 million and $258.7 million for the fourth quarter and full year 2023
The Company provides first quarter and full year 2024 revenue and adjusted diluted earnings per share guidance
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2023.
The Company’s worldwide revenue for the fourth quarter of 2023 totaled $354.0 million, which includes a $15.0 million RELISTOR milestone achievement, compared with $263.2 million for the fourth quarter of 2022, representing an increase of 34.5% over the prior year period. Full year 2023 worldwide revenues were $1.3 billion, compared with $935.1 million for the full year 2022, representing an increase of 38.6% over the prior year period.
The Company’s fourth quarter 2023 GAAP net income was $103.4 million, or $1.47 per fully diluted share, as compared to GAAP net loss of $119.2 million, or $1.74 per fully diluted share for the fourth quarter of 2022. Full year 2023 GAAP net income was $326.7 million, or $4.65 per fully diluted share, as compared to GAAP net income of $28.1 million, or $0.40 per fully diluted share for the full year 2022.
The Company’s fourth quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), were $1.75, as compared to $1.37 for the fourth quarter of 2022, representing an increase of approximately $0.38 or 28.0% from the prior year period. The Company’s full year 2023 adjusted fully diluted EPS, were $6.23, as compared to $4.22 for the full year 2022, representing an increase of approximately $2.01 or 47.7% from the prior year period.
Lastly, net cash provided by operating activities was $112.3 million and $305.3 million for the fourth quarter and full year 2023. Free Cash Flow was $100.2 million for the fourth quarter of 2023, as compared to $100.6 million for the fourth quarter of 2022, representing a decrease of approximately $0.4 million from the prior year period. Full year 2023 free cash flow was $258.7 million, as compared to $263.4 million for the full year 2022, representing a decrease of approximately $4.7 million from the prior year period.
“2023 was another stellar year at Lantheus, during which the Company delivered record revenues, earnings, cash flows and patient impact as we continued to advance our position as the leading radiopharmaceutical-focused company,” said Mary Anne Heino, Chief Executive Officer of Lantheus. “We are entering 2024 on a strong foundation and will continue to leverage our deep expertise in radiopharmaceuticals and our significant capital resources to advance and expand our pipeline.”
The Company provides its guidance for the first quarter and full year 2024 as follows:
Guidance Issued February 22, 2024
1Q 2024 Revenue
$347 million - $355 million
1Q 2024 Adjusted Fully Diluted EPS
$1.50 - $1.54
Guidance Issued February 22, 2024
FY 2024 Revenue
$1.41 billion - $1.445 billion
FY 2024 Adjusted Fully Diluted EPS
$6.50 - $6.70
Page 1 of 9


On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments, and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.
Internet Posting of Information
The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.
Conference Call and Webcast
As previously announced, the Company will host a conference call and webcast on Thursday, February 22, 2024, at 8:00 a.m. ET. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events.
A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.
The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.
The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.
About Lantheus Holdings, Inc.
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Non-GAAP Financial Measures
The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company’s reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “anticipate,” “believe,” “confident,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “introduce,” “may,” “momentum,” “plan,” “potential,” “predict,” “progress,” “project,” “promising,” “prospect,” “should,” “target,” “will,” “would” and other similar terms. Such forward-looking statements include our guidance for fiscal year 2024 and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment in which other imaging agents have been approved and are being commercialized, and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility; (iii) the global availability of Molybdenum-99 (“Mo-99”) and other raw materials and key components; (iv) our strategies, future
Page 2 of 9


prospects, and projected growth, including revenue related to our collaboration agreements with POINT Biopharma Global Inc. (“POINT”), including our ability to obtain FDA approval for PNT2002 and PNT2003; (v) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 as a research tool and under the license agreement through which we have rights to MK-6240, and to further develop and commercialize it as an approved product; (vi) our ability to successfully execute on our agreements with Perspective Therapeutics, Inc. (“Perspective”), including finalizing the license agreements in the event we exercise our options to do so, and satisfying the closing conditions for the sale of the Somerset, NJ manufacturing facility and related assets, the value of our current and any future equity interest in Perspective, and Perspective’s ability to successfully develop its alpha-particle therapy and innovative platform technology; (vii) the efforts and timing for clinical development, regulatory approval and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (viii) our ability to identify and acquire or in-license additional radiopharmaceutical therapeutic and diagnostic product opportunities in oncology and other strategic areas to grow our pipeline of products; and (ix) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
- Tables Follow -
Page 3 of 9


Lantheus Holdings, Inc.
Consolidated Statements of Operations
(in thousands, except per share data – unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
2023202220232022
Revenues$353,999 $263,166 $1,296,429 $935,061 
Cost of goods sold124,130 95,995 586,886 353,358 
Gross profit229,869 167,171 709,543 581,703 
Operating expenses
Sales and marketing35,264 26,983 141,736 100,243 
General and administrative40,295 39,639 125,458 133,584 
Research and development16,824 272,226 77,707 311,681 
Total operating expenses92,383 338,848 344,901 545,508 
Operating income (loss)137,486 (171,677)364,642 36,195 
Interest expense5,041 2,581 20,019 7,185 
Loss on extinguishment of debt— 588 — 588 
Other (income) loss(5,958)1,397 (66,320)1,703 
 Income (loss) before income taxes138,403 (176,243)410,943 26,719 
Income tax expense (benefit)35,023 (57,058)84,282 (1,348)
Net income (loss)$103,380 $(119,185)$326,661 $28,067 
Net income (loss) per common share:
Basic$1.51 $(1.74)$4.79 $0.41 
Diluted$1.47 $(1.74)$4.65 $0.40 
Weighted-average common shares outstanding:
Basic68,499 68,500 68,266 68,487 
Diluted70,092 68,500 70,239 70,671 
Page 4 of 9


Lantheus Holdings, Inc.
Consolidated Revenues Analysis
(in thousands – unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
20232022% Change20232022% Change
PYLARIFY$229,884 $160,642 43.1 %$851,303 $527,405 61.4 %
Other radiopharmaceutical oncology747 919 (18.7)%3,130 4,102 (23.7)%
Total radiopharmaceutical oncology230,631 161,561 42.8 %854,433 531,507 60.8 %
DEFINITY73,080 63,619 14.9 %279,768 244,993 14.2 %
TechneLite21,517 24,725 (13.0)%87,370 88,864 (1.7)%
Other precision diagnostics5,978 6,022 (0.7)%22,980 22,825 0.7 %
Total precision diagnostics100,575 94,366 6.6 %390,118 356,682 9.4 %
Strategic Partnerships and other revenue22,793 7,239 214.9 %51,878 46,872 10.7 %
Total revenues$353,999 $263,166 34.5 %$1,296,429 $935,061 38.6 %
Page 5 of 9


Lantheus Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands, except per share data – unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
2023202220232022
Net income (loss)$103,380 $(119,185)$326,661 $28,067 
Stock and incentive plan compensation14,172 8,124 50,507 29,262 
Amortization of acquired intangible assets11,308 8,307 46,440 33,225 
Campus consolidation costs679 — 3,864 — 
Contingent consideration fair value adjustments200 9,300 (9,275)34,700 
Non-recurring refinancing related fees70 221 70 
Non-recurring fees (a)
— — (54,523)(384)
Extinguishment of debt— 588 — 588 
Strategic collaboration and license costs— 265,856 — 266,356 
Acquisition-related costs169 169 676 1,037 
Impairment of long-lived assets— — 138,050 — 
ARO Acceleration and other related costs1,187 (968)2,232 2,119 
Other531 583 2,725 694 
Income tax effect of non-GAAP adjustments(b)
(8,950)(76,227)(70,043)(97,739)
Adjusted net income$122,681 $96,617 $437,535 $297,995 
Adjusted net income, as a percentage of revenues34.7 %36.7 %33.7 %31.9 %
Three Months Ended
December 31,
Year Ended
December 31,
2023202220232022
Net income (loss) per share - diluted$1.47 $(1.74)$4.65 $0.40 
Stock and incentive plan compensation0.20 0.12 0.72 0.41 
Amortization of acquired intangible assets0.16 0.12 0.66 0.47 
Campus consolidation costs0.01 — 0.06 — 
Contingent consideration fair value adjustments— 0.13 (0.13)0.49 
Non-recurring refinancing related fees— — — — 
Non-recurring fees (a)
— — (0.78)(0.01)
Extinguishment of debt— 0.01 — 0.01 
Strategic collaboration and license costs— 3.76 — 3.77 
Acquisition-related costs— — 0.01 0.01 
Impairment of long-lived assets— — 1.97 — 
ARO Acceleration and other related costs0.02 (0.01)0.03 0.03 
Other(c)
0.01 0.06 0.04 0.01 
Income tax effect of non-GAAP adjustments(b)
(0.12)(1.08)(1.00)(1.37)
Adjusted net income per share - diluted$1.75 $1.37 $6.23 $4.22 
Weighted-average common shares outstanding - diluted70,092 70,642 70,239 70,671 
(a)Includes the gain on sale of RELISTOR licensed intangible asset associated with net sales royalties of $51.8 million.
(b)The income tax effect of the adjustments between GAAP net loss and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
(c)This effect includes an adjustment related to the increase from basic to diluted shares as the Company changed from GAAP net loss to non-GAAP adjusted net income for the three months ended December 31, 2022.
Page 6 of 9


Lantheus Holdings, Inc.
Reconciliation of Free Cash Flow
(in thousands – unaudited)
Three Months Ended
December 31,
Year Ended
December 31,
2023202220232022
Net cash provided by operating activities$112,287 $105,352 $305,260 $281,781 
Capital expenditures(12,069)(4,724)(46,555)(18,347)
Free cash flow$100,218 $100,628 $258,705 $263,434 
Net cash (used in) provided by investing activities$(12,069)$(264,724)$5,939 $(276,547)
Net cash (used in) provided by financing activities$(450)$317,840 $(13,062)$311,691 
Page 7 of 9


Lantheus Holdings, Inc.
Condensed Consolidated Balance Sheets
(in thousands – unaudited)
December 31,
2023
December 31,
2022
Assets
Current assets
Cash and cash equivalents$713,656 $415,652 
Accounts receivable, net284,292 213,397 
Inventory64,029 35,475 
Other current assets16,683 13,092 
Assets held for sale7,159 — 
Total current assets1,085,819 677,616 
Property, plant and equipment, net146,697 122,166 
Intangibles, net151,985 315,285 
Goodwill61,189 61,189 
Deferred tax assets, net150,198 110,647 
Other long-term assets55,261 34,355 
Total assets$1,651,149 $1,321,258 
Liabilities and stockholders’ equity
Current liabilities
Current portion of long-term debt and other borrowings$823 $354 
Accounts payable41,189 20,563 
Short-term contingent liability— 99,700 
Accrued expenses and other liabilities145,338 127,084 
Total current liabilities187,350 247,701 
Asset retirement obligations22,916 22,543 
Long-term debt, net and other borrowings561,670 557,712 
Other long-term liabilities63,321 46,155 
Total liabilities835,257 874,111 
Total stockholders’ equity815,892 447,147 
Total liabilities and stockholders’ equity$1,651,149 $1,321,258 
Page 8 of 9


###
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
Page 9 of 9